The intent of the MoU is to forge a strong strategic partnership in a range of research areas and novel technologies in the field of pharma processes and product development
The US-based Purdue University has signed a Memorandum of Understanding (MoU) with Dr Reddy’s Laboratories (DRL) to strengthen pharmaceutical research and development, as reported in PTI.
According to a statement issued by the University, the intent of the MoU is to forge a strong strategic partnership in a range of research areas and novel technologies in the field of pharma processes and product development.
Suresh Garimella, Executive Vice-President for Research and Partnerships, Purdue, and his counterpart Amit Biswas, Executive Vice-President and Global Head of Integrated Product Development, signed the MoU last month.
The MoU will advance the ‘Purdue Moves’ drug discovery initiative to translate basic research into life-changing treatments.
“Purdue has tremendous strength in pharma drug discovery and development research, but we need additional partners to help translate our discoveries through the delivery of a medicine or technology,” Garimella said.
“The partnership with the Indian drug maker combines strengths that could lead to world-changing research,” he added.
Areas of planned collaborative research and education include targeted drug delivery, manufacturing technology, scale-up of pharmaceutical operations, process engineering, and research and development methodologies and technology.
“The collaboration will include student engagement and faculty exchanges and may include a site at Purdue Research Park,” the statement further said.
Biswas said the long-term research partnership will help accelerate innovative drug development and manufacturing excellence.
“The long-term research partnership augurs well for DRL’s philosophy of providing access to innovative, high-quality medicines to global patients at affordable cost,” he added.
- Advertisement -
Comments are closed.